Maziar Divangahi

Maziar Divangahi, Ph.D.

Professor of Medicine

Strauss Chair in Respiratory Diseases

Assoc Director, Meakins-Christie Laboratories

Assoc Director, McGill International TB Centre

Co-Leader, Program for Translational Research in Respiratory Diseases

RI-MUHC, Centre for Translational Biology


Research Institute of the McGill University Health Centre
1001 Boulevard Décarie
Glen Site Block E
Office EM3.2248
TRRD Mail Drop Point #EM32219
Montréal, Québec, Canada H4A 3J1

Tel: (514) 934-1934 Ext. 76431
maziar.divangahi [at]



Dr. Maziar Divangahi is a Professor of Medicine at McGill University. Dr. Divangahi is the

Associate Director of the Meakins-Christie Laboratories, Co-Leader of the Respiratory Program

at McGill University Health Centre, and an Associate Director of the McGill International TB

Centre. He is an internationally recognized pulmonary immunologist and the overarching focus of

his research program is to investigate the regulatory mechanisms involved in host resistance and

disease tolerance against major pulmonary bacterial (Mycobacterium tuberculosis) and viral

(influenza virus and SARS-CoV2) pathogens. He is currently investigating how to harness the

power of innate immunity in vaccine via reprogramming of hematopoietic stem cells. Throughout

his career, he has been a proliferative investigator publishing in outstanding journals and received

numerous awards, including a CIHR New Investigator Award, FRQS Award, and the CIHR

Foundation grant. His scholarly work has been recognized by election to the Royal Society of

Canada. He is currently holding the Strauss Chair in Respiratory Diseases.



Selected Publications

Kaufmann E, Khan N, Tran KA, Ulndreaj A, Pernet E, Fontes G, Lupien A, Desmeules P, McIntosh F, Abow A, Moorlag SJCFM, Debisarun P, Mossman K, Banerjee A, Karo-Atar D, Sadeghi M, Mubareka S, Vinh DC, King IL, Robbins CS, Behr MA, Netea MG, Joubert P, Divangahi M. BCG vaccination provides protection against IAV but not SARS-CoV-2. Cell Rep. 2022 Mar 8;38(10):110502. doi: 10.1016/j.celrep.2022.110502. Epub 2022 Feb 21. PMID: 35235831; PMCID: PMC8858710.

Divangahi M, Aaby P, Khader SA, Barreiro LB, Bekkering S, Chavakis T, van Crevel R, Curtis N, DiNardo AR, Dominguez-Andres J, Duivenvoorden R, Fanucchi S, Fayad Z, Fuchs E, Hamon M, Jeffrey KL, Khan N, Joosten LAB, Kaufmann E, Latz E, Matarese G, van der Meer JWM, Mhlanga M, Moorlag SJCFM, Mulder WJM, Naik S, Novakovic B, O'Neill L, Ochando J, Ozato K, Riksen NP, Sauerwein R, Sherwood ER, Schlitzer A, Schultze JL, Sieweke MH, Benn CS, Stunnenberg H, Sun J, van de Veerdonk FL, Weis S, Williams DL, Xavier R, Netea MG. Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nat Immunol. 2021 Jan;22(1):2-6. doi: 10.1038/s41590-020-00845-6. Erratum in: Nat Immunol. 2021 Jul;22(7):928. PMID: 33293712; PMCID: PMC8020292.

Khan N, Downey J, Sanz J, Kaufmann E, Blankenhaus B, Pacis A, Pernet E, Ahmed E, Cardoso S, Nijnik A, Mazer B, Sassetti C, Behr MA, Soares MP, Barreiro LB, Divangahi M. M. tuberculosis Reprograms Hematopoietic Stem Cells to Limit Myelopoiesis and Impair Trained Immunity. Cell. 2020 Oct 29;183(3):752-770.e22. doi: 10.1016/j.cell.2020.09.062. PMID: 33125891; PMCID: PMC7599081.

Moorlag SJCFM, Khan N, Novakovic B, Kaufmann E, Jansen T, van Crevel R, Divangahi M, Netea MG. β-Glucan Induces Protective Trained Immunity against Mycobacterium tuberculosis Infection: A Key Role for IL-1. Cell Rep. 2020 May 19;31(7):107634. doi: 10.1016/j.celrep.2020.107634. PMID: 32433977; PMCID: PMC7242907.

Khader SA, Divangahi M, Hanekom W, Hill PC, Maeurer M, Makar KW, Mayer-Barber KD, Mhlanga MM, Nemes E, Schlesinger LS, van Crevel R, Vankayalapati R(, Xavier RJ, Netea MG; Bill and Melinda Gates Foundation Collaboration for TB Vaccine Discovery Innate Immunity Working Group18. Targeting innate immunity for tuberculosis vaccination. J Clin Invest. 2019 Sep 3;129(9):3482-3491. doi: 10.1172/JCI128877. PMID: 31478909; PMCID: PMC6715374.

Tzelepis F, Blagih J, Khan N, Gillard J, Mendonca L, Roy DG, Ma EH, Joubert P, Jones RG, Divangahi M. Mitochondrial cyclophilin D regulates T cell metabolic responses and disease tolerance to tuberculosis. Sci Immunol. 2018 May 11;3(23):eaar4135. doi: 10.1126/sciimmunol.aar4135. PMID: 29752301.

Kaufmann E, Sanz J, Dunn JL, Khan N, Mendonça LE, Pacis A, Tzelepis F, Pernet E, Dumaine A, Grenier JC, Mailhot-Léonard F, Ahmed E, Belle J, Besla R, Mazer B, King IL, Nijnik A, Robbins CS, Barreiro LB, Divangahi M. BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis. Cell. 2018 Jan 11;172(1-2):176-190.e19. doi: 10.1016/j.cell.2017.12.031. PMID: 29328912.

External Links

Follow on PubMed

 International Innovation article on Maziar_Divangahi.pdf

International Innovation, published by Research Media, is the leading global dissemination resource for the wider scientific, technology and research communities, dedicated to disseminating the latest science, research and technological innovations on a global level. More information and a complimentary subscription offer to the publication can be found


Back to top